Retinitis Pigmentosa Treatment Update 2024. All ages under 18 over 18. But advances in gene therapy may soon help restore vision to a greater number of people.
Fda and eu regulators provide consistent advice that visual acuity may serve as primary endpoint to evaluate the effectiveness. Friday, may 3, 2024 time:
Irvine, Ca, August 29, 2023 — A Team Of Scientists From The University Of California, Irvine, Believe They Have Discovered A Special Antibody Which May Lead To A Treatment For Retinitis Pigmentosa, A Condition That Causes Loss Of Central Vision, As Well As Night And Color Vision.
Ocugen and the fda have agreed on trial design aspects including end point, patient enrollment strategy, and study duration.
Estimated Primary Completion Date :
But advances in gene therapy may soon help restore vision to a greater number of people.
The Ocu400 Phase 3 Limelight Clinical Trial Is Currently Underway And On Track To Meet The Company’s 2026 Bla.
Images References :
Announced That The Company Will Present On Its Innovative Modifier Gene Therapy Platform, Including Ocu400 For The Treatment Of Retinitis Pigmentosa, Ocu410 For The Treatment Of Geographic Atrophy, And Ocu410St For The Treatment Of Stargardt Disease At The Association For Research In Vision And.
View a complete list and schedule for all of the doheny eye institute and ucla stein eye institute research presentations.
Fda And Eu Regulators Provide Consistent Advice That Visual Acuity May Serve As Primary Endpoint To Evaluate The Effectiveness.